masoprocol has been researched along with Hypertension, Pulmonary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, C; Li, J; Lian, M; Ma, C; Shen, T; Shi, J; Wang, N; Wei, L; Yu, X; Zhang, C; Zhao, X; Zhu, D | 1 |
| Flynn, JT; Gee, MH; Havill, AM; Perkowski, SZ | 1 |
| Li, JX; Lu, CY; Oliver, JR; Philips, JB | 1 |
| Quinn, JV; Slotman, GJ | 1 |
4 other study(ies) available for masoprocol and Hypertension, Pulmonary
| Article | Year |
|---|---|
15-Lipoxygenase and 15-hydroxyeicosatetraenoic acid regulate intravascular thrombosis in pulmonary hypertension.
Topics: Animals; Arachidonate 15-Lipoxygenase; Blood Platelets; Cells, Cultured; Chemokine CCL2; Cytokines; Humans; Hydroxyeicosatetraenoic Acids; Hypertension, Pulmonary; Hypoxia; Indazoles; Lipoxygenase Inhibitors; Male; Masoprocol; Platelet Activation; Propionates; Pulmonary Artery; Random Allocation; Rats; Rats, Wistar; RNA Interference; RNA, Small Interfering; Signal Transduction; Thrombosis; Vascular Resistance | 2015 |
Role of prostaglandins and leukotrienes in complement-initiated lung vascular injury.
Topics: Animals; Catechols; Complement Activation; Epoprostenol; Hypertension, Pulmonary; Hypoxia; Leukocytes; Leukotriene B4; Masoprocol; Meclofenamic Acid; ortho-Aminobenzoates; Oxygenases; Prostaglandins; Pulmonary Circulation; Sheep; Zymosan | 1983 |
Delayed thromboxane or tumor necrosis factor-alpha, but not leukotriene inhibition, attenuates prolonged pulmonary hypertension in endotoxemia.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Endotoxins; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Imidazoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase; Masoprocol; Pentoxifylline; Sepsis; Swine; Thromboxane A2; Thromboxane B2; Thromboxane-A Synthase; Toxemia; Tumor Necrosis Factor-alpha | 1995 |
Platelet-activating factor and arachidonic acid metabolites mediate tumor necrosis factor and eicosanoid kinetics and cardiopulmonary dysfunction during bacteremic shock.
Topics: Aeromonas hydrophila; Animals; Arachidonic Acid; Azepines; Bridged Bicyclo Compounds, Heterocyclic; Eicosanoids; Female; Gram-Negative Bacterial Infections; Heart Diseases; Hemodynamics; Hypertension, Pulmonary; Lipoxygenase Inhibitors; Masoprocol; Oxazoles; Oxygen; Oxygen Consumption; Platelet Activating Factor; Prostaglandin-Endoperoxide Synthases; Shock, Septic; Swine; Thromboxane A2; Triazoles; Tumor Necrosis Factor-alpha | 1999 |